Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Fineline Cube Apr 27, 2026
Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Fineline Cube Apr 27, 2026
Company Drug

Sanofi Receives FDA Fast-Track Designation for Influenza and COVID-19 Combo Vaccine Candidates

Fineline Cube Dec 12, 2024

Sanofi (NASDAQ: SNY) has announced that it has received Fast-Track Designations from the US Food...

Company Deals

Youjia Biomedical and Livzon Pharmaceutical Group Ink Licensing Deal for siRNA Drug

Fineline Cube Dec 12, 2024

China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd. has signed a licensing agreement with compatriot firm...

Company Deals

Bayer AG to Acquire HiDoc Technologies and Launch Digital Health App Cara Care

Fineline Cube Dec 12, 2024

Germany-based Bayer AG (ETR: BAYN) has announced plans to acquire HiDoc Technologies GmbH in the...

Company Drug

Eli Lilly’s Imlunestrant Reduces Disease Progression in ER+/HER2- Advanced Breast Cancer: EMBER-3 Study

Fineline Cube Dec 12, 2024

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has published results from the Phase...

Policy / Regulatory

Shanghai Unveils Action Plan and Fund for Biopharma M&A Activities

Fineline Cube Dec 11, 2024

The Shanghai Municipal People’s Government has released the “Action Plan for Supporting Mergers and Acquisitions...

Company Deals

Fresenius Kabi Partners with Ori Biotech to Integrate IRO Platform with Cell Processing Systems

Fineline Cube Dec 11, 2024

Germany-based Fresenius Kabi, a leading name in healthcare, has struck an accord with Ori Biotech...

Company Drug

Arvinas and Pfizer Present Positive TACTIVE-U Sub-Study Data at SABCS 2024

Fineline Cube Dec 11, 2024

Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) have jointly presented preliminary data...

Company Deals

GSK Enters Multi-Program Partnerships with Relation Therapeutics for Fibrotic Diseases and Osteoarthritis

Fineline Cube Dec 11, 2024

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has formed two multi-program strategic partnerships with compatriot...

Company Drug

Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024

Fineline Cube Dec 11, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) presented updated results from the pivotal Phase III NATALEE...

Company Drug

Legend Biotech’s Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial

Fineline Cube Dec 11, 2024

China-based Legend Biotech Corporation (NASDAQ: LEGN) has released new data on minimal residual disease (MRD)...

Company Drug

Huadong Medicine’s Arcalyst Receives NMPA Approval for Recurrent Pericarditis Treatment

Fineline Cube Dec 11, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving another indication approval from the...

Company Drug

IMEIK Technology Receives NMPA Approval for Recombinant Human Hyaluronidase Clinical Study

Fineline Cube Dec 11, 2024

China-based IMEIK Technology Development Co., Ltd (SHE: 300896) has announced receiving approval from the National...

Company Drug

Patronus Biotech’s RSV Vaccine LYB005 Receives NMPA Approval for Clinical Study

Fineline Cube Dec 11, 2024

Guangzhou Patronus Biotech Co., Ltd., a vaccine start-up specializing in respiratory and infectious diseases, has...

Company Drug

Shanghai Pharmaceuticals’ SRD4610 Receives FDA Orphan Drug Designation for ALS Treatment

Fineline Cube Dec 11, 2024

China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced that the US Food and...

Company Drug

Sperogenix Therapeutics’ Agamree Receives NMPA Approval for Duchenne Muscular Dystrophy Treatment

Fineline Cube Dec 11, 2024

China-based rare disease specialist Sperogenix Therapeutics Limited has announced receiving marketing approval from the National...

Policy / Regulatory

Beijing Expands Medical Insurance Sharing to Near Relatives with New Policy

Fineline Cube Dec 11, 2024

The Beijing Municipal Medical Insurance Bureau has released a notification that significantly expands the scope...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-4394 and HRS-3802 Clinical Trials

Fineline Cube Dec 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...

Company Drug

Merck’s PD-1 Inhibitor Keytruda Approved by NMPA for Cervical Cancer Treatment in China

Fineline Cube Dec 11, 2024

US-based Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has announced receiving marketing approval from...

Company Drug

MSD’s Noxafil Receives NMPA Approval for Pediatric Use in Antifungal Treatment

Fineline Cube Dec 11, 2024

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced that China’s National Medical...

Company Drug

NMPA Approves Zynlonta for Relapsed or Refractory Large B-Cell Lymphoma Treatment

Fineline Cube Dec 11, 2024

The website of China’s National Medical Products Administration (NMPA) has indicated that the marketing filing...

Posts pagination

1 … 239 240 241 … 657

Recent updates

  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
  • Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.